PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34599882-3	2021	Particularly striking is the rapid acylation of spike on 10 cytosolic cysteines within the ER and Golgi.	Cysteine	70-79	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	48-53	
34558135-2	2021	The interaction between the SARS-CoV-2 spike protein and the human receptor angiotensin-converting enzyme 2, both of which contain several cysteine residues, is impacted by the disulfide-thiol balance in the host cell.	Cysteine	139-147	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	39-44	
32656452-5	2020	The receptor-binding domain of the viral spike proteins and ACE2 have several cysteine residues.	Cysteine	78-86	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	41-46	
34961524-3	2021	However, the palmitoylated cysteine residues of S protein, the effects of ZDHHC5 or GOLGA7 knockout on S protein"s subcellular localization, palmitoylation, pseudovirus entry and the enzyme for depalmitoylation of S protein are not clear.	Cysteine	27-35	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	48-49	
35123263-0	2022	The function of SARS-CoV-2 spike protein is impaired by disulfide-bond disruption with mutation at cysteine-488 and by thiol-reactive N-acetyl-cysteine and glutathione.	Cysteine	99-107	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	27-32	
34428449-4	2021	The Spike protein of SARS-CoV-2, the causative agent of COVID-19, has the most cysteine-rich cytoplasmic tail among known human pathogens in the closely-related family of beta-coronaviruses; however, it is unclear which of the cytoplasmic cysteines are S-acylated or the impact of this modification on viral infectivity.	Cysteine	239-248	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	4-9	
34428449-5	2021	Here we identify specific cysteine clusters in the Spike protein of SARS-CoV-2 that are targets of S-acylation.	Cysteine	26-34	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	51-56	
35578055-6	2022	The strong and stable binding of these safe and cheap vitamins at the important residues (R403, K417, Y449, Y453, N501, and Y505) in the S-protein-ACE2 interface and 3CLpro binding site residues especially active site residues (His 41 and Cys 145), indicating that they could be valuable repurpose drugs for inhibiting SARS-CoV-2 entry into the host and replication.	Cysteine	239-242	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	137-138	
35600063-2	2022	Here, we show how the key factors governing cysteine reactivity in proteins derived from combined quantum mechanical/continuum calculations led to a novel multi-targeting strategy against SARS-CoV-2, in contrast to developing potent drugs/vaccines against a single viral target such as the spike protein.	Cysteine	44-52	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	290-295	
35336938-1	2022	The spike proteins of enveloped viruses are transmembrane glycoproteins that typically undergo post-translational attachment of palmitate on cysteine residues on the cytoplasmic facing tail of the protein.	Cysteine	141-149	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	4-9	
35336938-3	2022	Here, we report that palmitoylation of the first five cysteine residues of the C-terminal cysteine-rich domain of the SARS-CoV-2 S protein are indispensable for infection, and palmitoylation-deficient spike mutants are defective in membrane fusion.	Cysteine	54-62	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	201-206	
35336938-3	2022	Here, we report that palmitoylation of the first five cysteine residues of the C-terminal cysteine-rich domain of the SARS-CoV-2 S protein are indispensable for infection, and palmitoylation-deficient spike mutants are defective in membrane fusion.	Cysteine	90-98	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	201-206	
35123263-7	2022	Taken together, these data indicate that Cys-488 in spike RBD is required for SARS-CoV-2 spike functions and infectivity, and could be a target of anti-SARS-CoV-2 therapeutics.	Cysteine	41-44	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	52-57	
35123263-7	2022	Taken together, these data indicate that Cys-488 in spike RBD is required for SARS-CoV-2 spike functions and infectivity, and could be a target of anti-SARS-CoV-2 therapeutics.	Cysteine	41-44	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	89-94